版本:
中国

BRIEF-Emergent awarded BARDA contract for advanced development of NuThrax

Sept 30 Emergent Biosolutions Inc

* Awarded BARDA contract for advanced development and delivery of NuThrax, a next generation anthrax vaccine, valued at up to $1.6 billion

* Contract includes options for an additional clinical study and post-marketing commitments valued at $48 million

* Company anticipates that FDA could authorize NuThrax for emergency use as early as 2018

* Contract includes options for delivery of additional 7.5 million to 50 million doses of NuThrax, valued about $255 million to up to $1.4 billion Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐